Corneal Versus Conjunctival Delivery Using a Delivery Device

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Compare the antihypertensive efficacy of three methods for installing Xalatan

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Latanoprost

Criteria

Inclusion Criteria:

• Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes

Exclusion Criteria:

• History of closed/barely open anterior chamber angle or a history of angle closure